Application Note

Apheresis Variability Control In Cell Therapy Manufacturing

Source: Cytiva
Cancer cells GettyImages-1310861779

T cell receptor (TCR)-based treatments, such CAR-T cell therapy, have become a focus of research and could eventually play an important role in standard of care for cancer. Making these treatments — and the processes used to create them — adaptable to many patients remains a key challenge in standardizing immunotherapies, due to inherent and significant source product variability.

Peripheral blood collection with apheresis processing is a preferred method for obtaining patient source material for cell therapies, as it is minimally invasive and results in the collection of a large number of cells. This article contains a collection of resources and information about apheresis products and their characteristics, manner of collection, and processing. Explore our best practices for apheresis collection and obtention of enriched product for cell therapies.

access the Application Note!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Drug Discovery Online? Subscribe today.

Subscribe to Drug Discovery Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Drug Discovery Online